A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

R. Targan, Stephan; B. Hanauer, Stephen; J. H. van Deventer, Sander; Mayer, Lloyd; H. Present, Daniel; Braakman, Tanja; L. DeWoody, Kimberly; Schaible, T; Rutgeerts, Paul

doi:10.1056/nejm199710093371502

Public

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

Published in New England Journal of Medicine • Oct 9, 1997

Authors:

Stephan R. Targan

Stephen B. Hanauer

Sander J. H. van Deventer

Abstract

BACKGROUND: Studies in animals and an open-label trial have suggested a role for antibodies to tumor necrosis factor alpha, specifically chimeric monoclonal antibody cA2, in the treatment of Crohn's disease. METHODS: We conducted a 12-week multicenter, double-blind, placebo-controlled trial of cA2 i...

Subject

Medicine

Crohn's disease

Monoclonal antibody

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!